NCT05433116
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05433116
Title Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Erlangen-Nuernberg Medical School
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
University Hospital Ulm, Otolaryngology & Head and Neck Surgery Ulm Baden-Wurttemberg 89070 Germany Details
University Hospital Augsburg, Radiation Oncology Augsburg Bavaria 86156 Germany Details
University Hospital Erlangen, Radiation Oncology Erlangen Bavaria 91054 Germany Details
University Hospital Regensburg, Clinic and Polyclinic for Radiotherapy Regensburg Bavaria 93053 Germany Details
University Hospital Frankfurt/M, Center for Radiology Frankfurt am Main Hesse 60590 Germany Details
University Hospital Giessen; Ear, nose and throat clinic Giessen Hesse 35392 Germany Details
University Hospital Düsseldorf, Radiation Oncology Düsseldorf North Rhine-Westphalia 40225 Germany Details
Saarland University Medical Center and Saarland University Faculty of Medicine, Clinic for Radiotherapy and Radiooncology Homburg Saarland 66421 Germany Details
Hospital Chemnitz, Radiation Oncology Chemnitz Saxony 09116 Germany Details
Gemeinschaftspraxis Hämatologie-Onkologie Dresden Saxony 01307 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field